CD274 and neoplasm: In the ATTRACTION-2 study of nivolumab in third-line metastatic GC patients, PD-L1 IHC was measured using the 28-8 assay, and defined as positive if ≥1% of tumor cells demonstrated staining (approximately equivalent to TPS ≥ 1%) (35).